A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function

Obesity Science & Practice
K G KheniserT Kasumov

Abstract

Metformin is a commonly prescribed anti-hyperglycaemic pharmacological agent, and it remains a staple in the management of type II diabetes. In addition to metformin's glucose lowering effects, research has indicated that metformin inhibits glycation-mediated and oxidative modification of lipoprotein residues. The purpose was to discuss the effects of metformin as it relates to high-density lipoprotein (HDL) and low-density lipoprotein (LDL) modification. The purpose was to conduct a narrative and pragmatic review on the effects of metformin as it pertains to HDL and LDL modification. High-density lipoprotein (HDL) concentration is a quantitative measure and therefore does not provide insight into its function, which is a qualitative property. Dysfunctional HDLs are unable to carry out functions normally associated with HDL because they can be modified by glycating agents. Metformin may counteract HDL dysfunction by abating HDL modification. Reductions in HDL modification may improve reverse cholesterol transport ability and thus possibly diminish cardiovascular risk. Similarly, metformin-mediated attenuations in LDL modification may reduce their atherogenic potency. Metformin may partially ameliorate HDL dysfunction and reduce...Continue Reading

References

Jan 19, 1999·Diabetes·P J BeisswengerB S Szwergold
Apr 13, 1999·Biochemical and Biophysical Research Communications·R G KhalifahB G Hudson
Apr 18, 2000·Diabetologia·C C HedrickA L Peters
Aug 16, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Anatol KontushM John Chapman
May 27, 2004·Diabetes Care·Ronald M Krauss
Jul 29, 2004·Journal of the American Dietetic Association·Teresia GoldbergHelen Vlassara
Nov 18, 2005·The International Journal of Biochemistry & Cell Biology·Adriana P MachadoMarisa Passarelli
Dec 13, 2006·American Journal of Nephrology·Murray Clarke, Martin Bennett
Apr 20, 2007·Journal of Cellular Physiology·Hong DingChris R Triggle
Feb 15, 2008·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·L SchurmanA M Cortizo
Mar 24, 2009·Metabolism: Clinical and Experimental·Meriem Mahrouf-YorgovJacqueline Peynet
Apr 21, 2009·Atherosclerosis·Kota MatsukiToshihiro Suda
Nov 12, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Jan 22, 2011·British Journal of Pharmacology·Cristina M SenaRaquel M Seiça
May 25, 2011·Proceedings of the National Academy of Sciences of the United States of America·Christina ChristoffersenBjörn Dahlbäck
Aug 19, 2011·American Journal of Physiology. Endocrinology and Metabolism·Sung Soo ChungKyong Soo Park
Aug 20, 2011·Diabetes·Cecilia MorgantiniSrinivasa T Reddy
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Aug 7, 2012·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·Y IshibashiS Yamagishi
Aug 28, 2013·The Journal of Clinical Endocrinology and Metabolism·R GoldbergE Barrett-Connor
Dec 24, 2013·Metabolism: Clinical and Experimental·Tiziana BacchettiGianna Ferretti
Mar 14, 2014·Redox Biology·Christiane OttAndreas Simm
Jul 30, 2014·Clinical Lipidology·Henry J PownallAntonio M Gotto
Aug 5, 2014·Clinical and Investigative Medicine. Médecine Clinique Et Experimentale·Masahiro OhiraIchiro Tatsuno
Sep 25, 2014·International Journal of Medical Sciences·Yanling WuWen Zhang
May 23, 2015·Journal of Lipid Research·Tomáš VaisarJay W Heinecke

❮ Previous
Next ❯

Citations

May 20, 2020·Frontiers in Endocrinology·Ziquan Lv, Yajie Guo
May 13, 2020·Cells·Ida Sofie GrønningsæterKimberley Joanne Hatfield

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.